To support those calculations please find the article "3 Breast Cancer Drugs That Could Boost Your Portfolio" by Amy Baldwin (Seeking Alpha) on the Internet. Just 2 data taken from that article:
- Peak Sales Estimates for NeuVax (Breast Cancer Vaccine) = 5B$
- Biotechnology industry trades at 8.7 times sales
Let's multiply 5B$ x .8.7 = 43.5B = 400$/share once reached the peak on sales.
Of course you could say that only strong bios can trade at 8.7 times sales. But what else would be Galena especially considering that NeuVax approval for breast cancer would open doors for its approval for other cancer indications?
Best regards hoping the better for Galena and for the patients who would benefit from its success.